TB-500 is a synthetic peptide fragment related to thymosin beta-4, a naturally occurring protein involved in cytoskeletal organization and cell migration. It is widely discussed in experimental and athletic communities for its potential roles in tissue repair and recovery.

Despite this interest, TB-500 typically occupies a gray zone between research chemical and unapproved therapeutic, with significant variation in how it is regulated and discussed across jurisdictions.

Proposed mechanisms for TB-500 draw from the broader biology of thymosin beta-4. High-level concepts include potential effects on:

• Actin dynamics and cytoskeletal remodeling
• Cell migration and wound-healing processes
• Angiogenesis and tissue remodelling

Much of this work is preclinical, and the degree to which specific TB-500 preparations reproduce these effects in humans is not firmly established.

TB-500 is generally not an approved, labeled medicine for human indications in many regions. It is often discussed in the context of musculoskeletal injuries, recovery from intense training, and other performance-adjacent scenarios.

Because regulatory status and quality standards vary, it is important to distinguish between regulated therapeutic use (where it exists) and informal or experimental practices. This page focuses on conceptual context rather than promoting any specific application.

TB-500 (Thymosin Beta-4) is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under category S2. Its use is banned in and out of competition.

Notable doping cases involving Thymosin Beta-4 include:

• Essendon Football Club (AFL): 34 players received 12-month bans in a high-profile case involving Thymosin Beta-4 injections.
• Emma Brooks (Volleyball): Sanctioned for 4 years (2025) for violations involving TB-500 and BPC-157.
• Anthony McCauley (Triathlon): Accepted a sanction in 2025 for possession and use of TB-500 and BPC-157.

Reported experiences have included local injection-site reactions, headache, and nonspecific symptoms such as fatigue. However, there is a lack of large, rigorously controlled safety studies.

Uncertainties around long-term effects, interactions with other therapies, and variability in product composition underscore the importance of cautious interpretation and adherence to local laws and regulations.

While standardized clinical dosing guidelines for TB-500 are not established, research and anecdotal reports share common themes regarding preparation and administration.

This information summarizes commonly discussed practices and does not constitute a medical recommendation. Product potency and purity can vary significantly.

TB-500 is commonly listed as a lyophilized peptide powder for reconstitution. In some catalogs it appears in combination products (e.g., with BPC-157 or other peptides) that seek to bundle multiple mechanistic themes such as tissue repair and anti-inflammatory effects.

In this catalog, TB-500 appears both as a single-agent entry and within certain combination SKUs. These listings are structural and should not be interpreted as endorsements of specific stacks, preparations, or practices.

Preclinical studies have examined thymosin beta-4 and related fragments in models of cardiac injury, wound healing, and musculoskeletal repair. These studies suggest potential biologic activity but do not directly translate into approved clinical indications for TB-500 products.

Human data remain relatively sparse and heterogeneous. When reviewing the literature, it is important to differentiate between mechanistic studies, exploratory trials, and marketing narratives.

A future FAQ section may address high-level questions about how to interpret TB-500 research, how it compares conceptually with other healing-focused peptides, and what open questions exist. Responses will focus on concepts, not regimens.